Back to Search Start Over

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Authors :
Boekel, L.
Stalman, E.W.
Wieske, L.
Hooijberg, F.
Dam, K.P.J. van
Besten, Y.R.
Kummer, L.Y.
Steenhuis, M.
Kempen, Z.L.E. van
Killestein, J.
Volkers, A.G.
Tas, S.W.
Kooi, A.J. van der
Raaphorst, J.
Löwenberg, M.
Takkenberg, R.B.
d'Haens, G.
Spuls, P.I.
Bekkenk, M.W.
Musters, A.H.
Post, N.F.
Bosma, A.L.
Hilhorst, M.L.
Vegting, Y.
Bemelman, F.J.
Voskuyl, A.E.
Broens, B.
Sanchez, A.
Els, C. van
Wit, J. de
Rutgers, A.
Leeuw, K. de
Horváth, B.
Verschuuren, J.
Ruiter, A.M. de
Ouwerkerk, L.
Woude, D. van der
Allaart, C.F.
Teng, Y.K.O.
Paassen, P. van
Busch, M.H.
Jallah, P.B.P.
Brusse, E.
Doorn, P.A. van
Baars, A.E.
Hijnen, D.J.
Schreurs, C.R.G.
Pol, W.Ludo van der
Goedee, H.S.
Vogelzang, E.H.
Leeuw, M. de
Atiqi, S.
Vollenhoven, R. van
Gerritsen, M
Horst-Bruinsma, I.E. van der
Lems, W.F.
Nurmohamed, M.T.
Boers, Maarten
Keijzer, Sofie
Keijser, J. de
Sandt, C.
Boogaard, A.
Cristianawati, O.
Brinke, A. Ten
Verstegen, N.J.
Zwinderman, K.A.H.
Ham, S.M. van
Rispens, T.
Kuijpers, T.W.
Wolbink, G.
Eftimov, F.
Boekel, L.
Stalman, E.W.
Wieske, L.
Hooijberg, F.
Dam, K.P.J. van
Besten, Y.R.
Kummer, L.Y.
Steenhuis, M.
Kempen, Z.L.E. van
Killestein, J.
Volkers, A.G.
Tas, S.W.
Kooi, A.J. van der
Raaphorst, J.
Löwenberg, M.
Takkenberg, R.B.
d'Haens, G.
Spuls, P.I.
Bekkenk, M.W.
Musters, A.H.
Post, N.F.
Bosma, A.L.
Hilhorst, M.L.
Vegting, Y.
Bemelman, F.J.
Voskuyl, A.E.
Broens, B.
Sanchez, A.
Els, C. van
Wit, J. de
Rutgers, A.
Leeuw, K. de
Horváth, B.
Verschuuren, J.
Ruiter, A.M. de
Ouwerkerk, L.
Woude, D. van der
Allaart, C.F.
Teng, Y.K.O.
Paassen, P. van
Busch, M.H.
Jallah, P.B.P.
Brusse, E.
Doorn, P.A. van
Baars, A.E.
Hijnen, D.J.
Schreurs, C.R.G.
Pol, W.Ludo van der
Goedee, H.S.
Vogelzang, E.H.
Leeuw, M. de
Atiqi, S.
Vollenhoven, R. van
Gerritsen, M
Horst-Bruinsma, I.E. van der
Lems, W.F.
Nurmohamed, M.T.
Boers, Maarten
Keijzer, Sofie
Keijser, J. de
Sandt, C.
Boogaard, A.
Cristianawati, O.
Brinke, A. Ten
Verstegen, N.J.
Zwinderman, K.A.H.
Ham, S.M. van
Rispens, T.
Kuijpers, T.W.
Wolbink, G.
Eftimov, F.
Source :
The Lancet. Rheumatology; e417; e429; 2665-9913; 6; 4; ~The Lancet. Rheumatology~e417~e429~~~2665-9913~6~4~~
Publication Year :
2022

Abstract

Item does not contain fulltext<br />BACKGROUND: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with immunosuppressants, but clinical data on breakthrough infections are still scarce. The primary objective of this study was to compare the incidence and severity of SARS-CoV-2 breakthrough infections between patients with immune-mediated inflammatory diseases using immunosuppressants, and controls (patients with immune-mediated inflammatory diseases not taking immunosuppressants and healthy controls) who had received full COVID-19 vaccinations. The secondary objective was to explore determinants of breakthrough infections of the delta (B.1.617.2) variant of SARS-CoV-2, including humoral immune responses after vaccination. METHODS: In this substudy, we pooled data collected in two large ongoing prospective multicentre cohort studies conducted in the Netherlands (Target to-B! [T2B!] study and Amsterdam Rheumatology Center COVID [ARC-COVID] study). Both studies recruited adult patients (age ≥18 years) with immune-mediated inflammatory diseases and healthy controls. We sourced clinical data from standardised electronic case record forms, digital questionnaires, and medical files. We only included individuals who were vaccinated against SARS-CoV-2. For T2B!, participants were recruited between Feb 2 and Aug 1, 2021, and for ARC-COVID, participants were recruited between April 26, 2020, and March 1, 2021. In this study we assessed data on breakthrough infections collected between July 1 and Dec 15, 2021, a period in which the delta SARS-CoV-2 variant was the dominant variant in the Netherlands. We defined a SARS-CoV-2 breakthrough infection as a PCR-confirmed or antigen test-confirmed SARS-CoV-2 infection that occurred at least 14 days after vaccination. All breakthrough infections during this period were assumed to be due to the delta variant due to its dominance during the study period. We analysed

Details

Database :
OAIster
Journal :
The Lancet. Rheumatology; e417; e429; 2665-9913; 6; 4; ~The Lancet. Rheumatology~e417~e429~~~2665-9913~6~4~~
Publication Type :
Electronic Resource
Accession number :
edsoai.on1367134635
Document Type :
Electronic Resource

Tools

Authors Abstract Subjects Details